Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GEM103 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| Dose 1 | EXPERIMENTAL | A single dose of GEM103 will be administered via intravitreal injection. This arm will be the lowest dose of GEM103 |
| Dose 2 | EXPERIMENTAL | A single dose of GEM103 will be administered via intravitreal injection. This arm will be the medium dose of GEM103 |
| Dose 3 | EXPERIMENTAL | A single dose of GEM103 will be administered via intravitreal injection. This arm will be a higher dose of GEM103 |
| Dose 4 | EXPERIMENTAL | A single dose of GEM103 will be administered via intravitreal injection. This arm will be the highest (extension) dose of GEM103 |
| Name | Type | Description |
|---|---|---|
| GEM103 | BIOLOGICAL | GEM103 |
Inclusion Criteria: 1. At least 50 years old at the time of signed informed consent 2. Able to cooperate sufficiently for adequate ophthalmic visual function testing and anatomic assessment and provide informed consent prior to initiation of any study procedure 3. Best corrected visual acuity (BCVA...
GEM103 is an investigational monoclonal antibody being developed for dry age-related macular degeneration, specifically for geographic atrophy secondary to dry AMD. It is designed to address retinal degeneration in patients with this condition. The drug is currently in clinical development and is not yet approved by regulatory authorities.
GEM103 is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. The drug is being studied for its potential to treat geographic atrophy in dry age-related macular degeneration, a condition characterized by retinal degeneration.
GEM103 is being developed by Disc Medicine, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol IRON. Disc Medicine is conducting clinical research to evaluate the safety and tolerability of GEM103 in patients with dry age-related macular degeneration.
GEM103 is in Phase 1 clinical development. A first-in-human study has been completed to evaluate its safety and tolerability in patients with geographic atrophy secondary to dry age-related macular degeneration. The drug remains investigational and has not received FDA approval.
GEM103 has one completed Phase 1 clinical trial, identified as NCT04246866. This first-in-human study evaluated the safety and tolerability of GEM103 in 12 participants with geographic atrophy secondary to dry age-related macular degeneration. The trial was conducted in the United States and enrolled adults aged 50 years and older.
No alternative names for GEM103 have been identified. The drug is known only by its code name GEM103 and is being developed by Disc Medicine, Inc. for the treatment of dry age-related macular degeneration.